Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045227 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00045227: Completed Phase 2 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
NCT00045227 is a Phase 2 study of Prostate Cancer that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045227, a Phase 2 study of Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without docetaxel in treating patients who have metastatic prostate cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- BIOLOGICAL sargramostim
- BIOLOGICAL recombinant fowlpox-prostate specific antigen vaccine
- BIOLOGICAL recombinant vaccinia prostate-specific antigen vaccine
- BIOLOGICAL recombinant vaccinia-B7.1 vaccine
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00045227 record still lists
NCT00045227 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which docetaxel is the first listed.
NCT00045227 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00045227 about?
NCT00045227 is a clinical study titled "Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial ...
What is the current status of trial NCT00045227?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-08. Estimated completion is 2007-10.
What conditions does trial NCT00045227 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00045227?
The interventions under investigation include: docetaxel (DRUG), sargramostim (BIOLOGICAL), recombinant fowlpox-prostate specific antigen vaccine (BIOLOGICAL), recombinant vaccinia prostate-specific antigen vaccine (BIOLOGICAL), recombinant vaccinia-B7.1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00045227?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00045227 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia